Advaxis Science & Operations Officer Moderates Live Vaccine Panel at Cancer Drug Research Conference

Paradise Point Resort Hotel, San Diego, CA | January 27 -28, 2011

NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., (OTCBB: ADXS) the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, “Live Cancer Vaccines.”

Topics addressed by the panel included:

  • The novelty of live vaccines which offer immunologic therapeutic alternatives never available previously; with new mechanisms of action and unprecedented efficacy in certain indications.
  • The safety of live vaccines is significantly greater than chemotherapy or radiotherapy, and is much better tolerated by patients.
  • Not only do these agents possess immunologic efficacy, but they appear to work well with chemotherapy and radiation, thus offering additional alternatives not previously possible.

Live vaccines are a developing area of science that has the potential to change the way in which drugs are delivered to patients. Unlike conventional therapy where biologically active chemicals are administered, live vaccines infect the patient’s cells to be treated and make the active drugs from the inside of these cells, where they are used.

Some noteworthy publicly-traded healthcare companies and governmental institutions in attendance included: Pfizer Oncology (NYSE: PFE), Genentech Roche (OTCQX: RHHBY), the National Cancer Institute (NCI), and the Tumor Immunology and Biology, Medical Oncology Branch of National Institutes of Health (NIH).

About the 8th Annual Cancer Drugs Research and Development Conference

The 8th Annual Cancer Drugs Research and Development Conference on January 27-28, 2011 in San Diego, California, US will provide an extensive look at the successes as well as the challenges that face modern cancer drug development and provide you with an update on cancer drugs currently in development through clinical trials. A look at live cancer vaccines, novel compounds and antibody drug conjugates will prime delegates and guests with the future direction of cancer drugs with key topics to be discussed by leading experts.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, four (4) clinical trials – two (2) in progress and two (2) to be started – and two (2) Cooperative Research and Development Agreements (CRADA) with the National Cancer Institute and the Department of Homeland Security, respectively. The Company conducts direct and strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the University of Pittsburgh and the University of British Columbia.

Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.



CONTACT:

Advaxis, Incorporated
Conrad F. Mir, 732-545-1590 (Office)
Executive Director
732-545-1084 (FAX)
[email protected]
or
Advaxis, Incorporated
Diana Moore, 732-545-1590
Analyst
732-545-1084 (FAX)
[email protected]

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo